199 related articles for article (PubMed ID: 38338893)
21. Contribution of Human Retroviruses to Disease Development-A Focus on the HIV- and HERV-Cancer Relationships and Treatment Strategies.
Liu CH; Grandi N; Palanivelu L; Tramontano E; Lin LT
Viruses; 2020 Aug; 12(8):. PubMed ID: 32759845
[TBL] [Abstract][Full Text] [Related]
22. Do Antiretroviral Drugs Protect From Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?
Morandi E; Tanasescu R; Tarlinton RE; Constantin-Teodosiu D; Gran B
Front Immunol; 2018; 9():3092. PubMed ID: 30740110
[TBL] [Abstract][Full Text] [Related]
23. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
24. Human endogenous retroviruses in neurologic disease.
Christensen T
APMIS; 2016; 124(1-2):116-26. PubMed ID: 26818266
[TBL] [Abstract][Full Text] [Related]
25. Effect of human endogenous retrovirus-K env gene knockout on proliferation of ovarian cancer cells.
Ko EJ; Kim ET; Kim H; Lee CM; Koh SB; Eo WK; Kim H; Oh YL; Ock MS; Kim KH; Cha HJ
Genes Genomics; 2022 Sep; 44(9):1091-1097. PubMed ID: 35802343
[TBL] [Abstract][Full Text] [Related]
26. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
27. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
[TBL] [Abstract][Full Text] [Related]
28. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
Singh S; Davis R; Alamanda V; Pireddu R; Pernazza D; Sebti S; Lawrence N; Chellappan S
Mol Cancer Ther; 2010 Dec; 9(12):3330-41. PubMed ID: 21139044
[TBL] [Abstract][Full Text] [Related]
29. Human endogenous retroviruses and cancer.
Gonzalez-Cao M; Iduma P; Karachaliou N; Santarpia M; Blanco J; Rosell R
Cancer Biol Med; 2016 Dec; 13(4):483-488. PubMed ID: 28154780
[TBL] [Abstract][Full Text] [Related]
30. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C; Molina JM; Cahn P; Lombaard J; Supparatpinyo K; Kumar S; Campbell H; Wan H; Teal V; Jin Xu Z; Asante-Appiah E; Sklar P; Teppler H; Lahoulou R;
Lancet HIV; 2024 Feb; 11(2):e75-e85. PubMed ID: 38141637
[TBL] [Abstract][Full Text] [Related]
32. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.
Schiavetti F; Thonnard J; Colau D; Boon T; Coulie PG
Cancer Res; 2002 Oct; 62(19):5510-6. PubMed ID: 12359761
[TBL] [Abstract][Full Text] [Related]
33. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Atefi M; Avramis E; Lassen A; Wong DJ; Robert L; Foulad D; Cerniglia M; Titz B; Chodon T; Graeber TG; Comin-Anduix B; Ribas A
Clin Cancer Res; 2014 Jul; 20(13):3446-57. PubMed ID: 24812408
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
35. Salviolone from
Zanrè V; Campagnari R; Cerulli A; Masullo M; Cardile A; Piacente S; Menegazzi M
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163058
[TBL] [Abstract][Full Text] [Related]
36. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
Qazzaz H; Parganas C; Cory TJ
Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
[TBL] [Abstract][Full Text] [Related]
38. Taraxasterol attenuates melanoma progression via inactivation of reactive oxygen species-mediated PI3K/Akt signaling pathway.
Liu W; Yu Q; Wang F; Li Y; Zhang G; Tao S
Hum Exp Toxicol; 2022; 41():9603271211069034. PubMed ID: 35128947
[No Abstract] [Full Text] [Related]
39. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.
Górniak P; Wasylecka-Juszczyńska M; Ługowska I; Rutkowski P; Polak A; Szydłowski M; Juszczyński P
Mol Oncol; 2020 Aug; 14(8):1817-1832. PubMed ID: 32330348
[TBL] [Abstract][Full Text] [Related]
40. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines.
Büscher K; Trefzer U; Hofmann M; Sterry W; Kurth R; Denner J
Cancer Res; 2005 May; 65(10):4172-80. PubMed ID: 15899808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
